Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.

Conclusions: Pre-transplant CMV-specific ELISPOT assay appears to predict the development of CMV infections after KT in recipients at moderate risk such as CMV-seropositive recipients (Clinical Trial Registration Number NCT 02025335). PMID: 29865778 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29865778?dopt=Abstract

Source: The Korean Journal of Internal Medicine - June 6, 2018 Category: Internal Medicine Authors: Kim T, Lee HJ, Kim SM, Jung JH, Shin S, Kim YH, Sung H, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH, Han DJ Tags: Korean J Intern Med Source Type: research